Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Vaxcyte Inc., 3 years.
Vaxcyte Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Vaxcyte Inc. June 6, 202497.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 15, 2026 | Vaxcyte Inc. | Grant or award | +2,265 | — | — |
| Mar 26, 2026 | COMPASS Pathways Plc | Grant or award | +75,000 | — | — |
| Mar 11, 2026 | COMPASS Pathways Plc | Shares withheld for tax | −1,781 | $6.89 | $12,271 |
| Mar 2, 2026 | COMPASS Pathways Plc | Shares withheld for tax | −4,467 | $7.02 | $31,358 |
| Jun 12, 2025 | Vaxcyte Inc. | Grant or award | +3,041 | — | — |
| Mar 11, 2025 | COMPASS Pathways Plc | Grant or award | +25,000 | — | — |
| Mar 3, 2025 | COMPASS Pathways Plc | Shares withheld for tax | −4,468 | $3.67 | $16,398 |
| Jan 15, 2025 | Vaxcyte Inc. | Option exercise | +6,250 | $22.70 | $141,875 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −146 | $80.46 | $11,747 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −215 | $81.53 | $17,529 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −1,136 | $82.89 | $94,163 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −1,202 | $83.93 | $100,884 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −1,043 | $85.29 | $88,957 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −966 | $86.26 | $83,327 |
| Jan 15, 2025 | Vaxcyte Inc. | Open-market sale | −1,013 | $87.38 | $88,516 |
Questions about Teri Loxam
What boards is Teri Loxam on?
Teri Loxam sits on the board of Vaxcyte Inc.
How long has Teri Loxam served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.